Middle East Molecular Biology Sources- MEMBS

BioSpace | February 20, 2020

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...

openPR.com | April 13, 2020

Advance Market Analytics released the research report of Global Coronavirus Testing Kits Market, offers a detailed overview of the factors influencing the global business scope. Global Coronavirus Testing Kits Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Global Coronavirus Testing Kits. This Report covers the emerging player's...

INDUSTRIAL IMPACT

Riverside Partners | February 02, 2022

Syner-G BioPharma Group a leading provider of Chemistry, Manufacturing, and Controls technical, regulatory, and compliance consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of Impact Pharmaceutical Services. Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post-marketing of drugs and biologics. ...

CELL AND GENE THERAPY

BioMarin Pharmaceutical Inc. | December 17, 2021

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...